Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis: GI Signals

IBD meta analysis · n=7,897 · Jul 1, 2026 · Inflamm Bowel Dis · IF 4.5

Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis.

New evidencesystematic reviewmeta-analysisepidemiologyCrohn's disease

Clinical takeawayDisability is common in IBD and persists even in remission (about 27 percent), so consider periodically assessing it with a validated tool (IBD Disk or IBD-Disability Index) rather than assuming remission equals full function.

What it foundThe pooled prevalence of moderate-to-severe disability in IBD patients is 29.6%, higher in Crohn disease (36.9%) vs. ulcerative colitis (30.8%) and in active disease (56.9%) vs. inactive disease (27.0%).

ContextThis study confirms the high burden of disability in IBD, particularly in Crohn disease and active disease, and highlights the need for routine disability assessment, which is not yet standard practice.

Emergingsuggested applicable standard· ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes)

Decision at stakeassessing disability in IBD patients as part of comprehensive care

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. Treat mild-moderate disease with 5-ASA by route and extent (suppository for proctitis, enema for left-sided, oral plus rectal for extensive); if 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by EFFICACY TIER, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab; intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab; lower: adalimumab. PREVIOUSLY TNF-EXPOSED, higher efficacy: tofacitinib, upadacitinib, ustekinumab; lower: adalimumab, vedolizumab, ozanimod, etrasimod - S1P modulators are weakest in exactly this group. Do not cycle within the anti-TNF class after primary non-response; switch mechanism. Apply treat-to-target (STRIDE-II) to endoscopic improvement (MES 0-1). Screen for acute severe UC by Truelove-Witts and admit for IV steroids. Begin CRC surveillance 8-10 years after DIAGNOSIS for extensive or left-sided disease; isolated proctitis follows average-risk screening.

ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes) ↗

Nardone OM … Barberio B · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink